What are the risks and benefits of long-acting anticholinergics in patients with asthma?

MOspace/Manakin Repository

Breadcrumbs Navigation

What are the risks and benefits of long-acting anticholinergics in patients with asthma?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/11381

[+] show full item record


Title: What are the risks and benefits of long-acting anticholinergics in patients with asthma?
Author: Elmore, Lindsey; Johnson, Kevin
Keywords: refractory asthma
symptom relief
tiotropium
Date: 2011-08
Publisher: Family Physicians Inquiries Network
Citation: Evidence Based Practice 14(8): 08-09.
Series/Report no.: Help Desk Answers
Abstract: Long-acting anticholinergics (LAAchs) have been demonstrated to improve peak expiratory flow (PEF) and forced expiratory volume over 1 second (FEV1) in patients with asthma. (SOR: C, based on disease-oriented outcomes.) They produce a small improvement in symptoms when added to inhaled steroid therapy, similar to that achieved by adding a long-acting beta-agonist. (SOR: B, based on a single RCT.) However, long-term safety is unclear.
URI: http://hdl.handle.net/10355/11381

This item appears in the following Collection(s)

[+] show full item record